News Chart Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 15:57:34 03/09/2026 BST			5-day change	1st Jan Change
14.40 ^USD	+1.23%		+0.63%	-8.10%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

6f7e5f094d0e8f71322a186a91e.-r12fbpObealf6xcR0Ebwh4lvYFTHymZL42hKdpEZ1k.t8QwJ9h2KoCTN-tsDgRBh25s8rMLSW3QRsXxRrN3NQyVkDsf8gcoucopmA~308914a47fc4d081fa542b3cdafbc3eb